Metastatic hepatocellular carcinoma

Clinical Oncology

Volumn 15, Issue 5, 2003, Pages 288-294

  Kummar, Shivaani ^a   Shafi, N Q ^b  

^a YALE CANCER CENTER   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Cirrhosis; Haemorrhagic brain metastasis; Hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; ANGIOGENESIS INHIBITOR; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CD34 ANTIGEN; CISPLATIN; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; IMMUNOMODULATING AGENT; MESSENGER RNA; MONOCLONAL ANTIBODY; OCTREOTIDE; RECOMBINANT ALPHA2B INTERFERON; SOMATOSTATIN DERIVATIVE; THALIDOMIDE; VASCULOTROPIN;

ABDOMINAL DISEASE; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADRENAL METASTASIS; ADULT; ALCOHOL LIVER CIRRHOSIS; ASCITES; AUTOPSY; BRAIN INJURY; BRAIN METASTASIS; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; DEATH; HEPATOMEGALY; HUMAN; HUMAN CELL; HUMAN TISSUE; JAUNDICE; LEG EDEMA; LIVER CELL CARCINOMA; LUNG METASTASIS; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MALE; MICROSCOPY; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SPLENOMEGALY; THORAX RADIOGRAPHY; TREATMENT PLANNING; TUMOR CELL; TUMOR EMBOLISM;

EID: 0042130316     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(03)00067-0     Document Type: Review

References (40)

1. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphological features and genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000;124:1599-1607.
2. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462-503.
3. Monto A, Wright TL. The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol 2001;28:441-449.
4. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-1801.
5. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
6. Sherman M. Surveillance for hepatocellular carcinoma. Semin Oncol 2001;28:450-459.
7. Ishaq KG, Goodman ZD, Stocker JT. Tumors of liver and intrahepatic bile ducts, Atlas of tumor pathology. Third Series, fascicle 31. Bethesda, MD: Armed Forces Institute of Pathology, 2001.
8. Chafner F, Popper H. Capillarization of the hepatic sinusoids in man. Gastroenterology 1963;4:239-242.
9. Kassianides C, Kew MC. The clinical manifestations and natural history of hepatocellular carcinoma. Gastroenterol Clin N Am 1987; 16:553-562.
10. Yuki K, Hirohashi S, Sakamoto M, Kanai T, Shimasato Y. Growth and spread of hepatocellular carcinoma: a review of 240 autopsy cases. Cancer 1990;66:2174-2179.
11. Chin A, Liang TS, Borislow AJ. Initial presentation of hepatocellular carcinoma as a mandibular mass: case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:457-460.
12. Doval DC, Rao CR, Acharya R, et al. Hepatocellular carcinoma metastatic to bones (case report with review of literature). Indian J Cancer 1995;32:31-35.
13. Byrd RP, Roy TM, Korhage LG, Fields CL. Hepatocellular carcinoma presenting as a mediastinal mass. J Ky Med Assoc 1994;92:260-262.
14. Noguchi H, Hirai K, Itano S, et al. Small hepatocellular carcinoma with intravascular tumor growth into the right atrium. J Gastroenterol 1994;29:41-46.
15. Kim M, Na DL, Park SH, Jeon BS, Roh JK. Nervous system involvement by metastatic hepatocellular carcinoma. J Neurooncol 1998;36:85-90.
16. Friedman HD. Hepatocellular carcinoma with central nervous system metastasis: a case report and literature review. Med Pediatr Oncol 1991;19:139-144.
17. Kar S, Carr BI. Detection of liver cells in peripheral blood of patients with advanced-stage hepatocellular carcinoma. Hepatology 1995;21:403-407.
18. Ueno S, Tanabe G, Sako K, et al. Discrimination value of the new Western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Hepatology 2001;34:529-534.
19. Farinati F, Rinalid M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000;89:2266-2273.
20. Vauthey JN, Lauwers GY, Esnaolo NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002;20:1527-1536.
21. Greene FL, Page DL, Fleming ID, et al. American Joint Committee on Cancer Staging Handbook, sixth edn, 2002.
22. Chow NH, Hsu PI, Lin XZ, et al. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 1997;28:698-703.
23. Poon RT, Ng IO, Lau C, et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 2002;20:1775-1785.
24. Ng IOL, Lai ECS, Fan ST, Ng MMT, So MKP. Prognostic significance of pathologic features of hepatocellular carcinoma. Cancer 1995;76:2443-2448.
25. Kawata A, Une HM, Uchino JK. Tumor infiltrating lymphocytes and prognosis of hepatocellular carcinoma. Jpn J Clin Oncol 1992;22:256-263.
26. El-Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N. The clinicopathological significance of heparanse and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 2001;7:1299-1305.
27. Inagawa S, Itabashi M, Adachi S, et al. Expression and prognostic roles of β-catenin in hepatocellular carcinoma. Clin Cancer Res 2002;8:450-456.
28. Little SA, Fong Y. Hepatocellular carcinoma: current surgical management. Semin Oncol 2001;28:474-486.
29. Aguayo A, Patt YZ. Nonsurgical treatment of hepatocellular carcinoma. Semin Oncol 2001;28:503-513.
30. Morimoto Y, Tanaka Y, Itoh T, Yamamoto S, Mizuno H, Fushimi H. Spontaneous necrosis of hepatocellular carcinoma: a case. Digest Surg 2002;19:413-418.
31. Takeda Y, Togashi H, Shinzawa H, et al. Spontaneous regression of hepatocellular carcinoma and review of literature. J Gastrointestinal Hepatol 2000;15:1079-1086.
32. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997;8:117-136.
33. Leung TWT, Johnson PJ. Systemic therapy for hepatocellular carcinoma. Semin Oncol 2001;28:514-520.
34. Fong Y, Kemeny N, Lawrence TS. Cancer of the liver and biliary tree. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer, Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams and Wilkins, 2001:11621204.
35. Lozano RD, Patt YZ, Hassan MM, et al. Oral capecitabine (xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer). Proc Am Soc Clin Oncol 2000;00:264a.
36. Leung TWT, Patt YZ, Lau WY, et al. Complete pathologic remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999; 5:1676-1681.
37. Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002; 94:421-427.
38. Gallo C, Daniele B, Gaeta GB, et al. Tamoxifen in the treatment of hepatocellular carcinoma: a randomized controlled trial. Lancet 1998;352:17-20.
39. Kin M, Torimura T, Ueno T, et al. Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats. Int J Oncol 2000;16:375-382.
40. Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of thalomid (thaldomide) for treatment of non-resectable hepatocellular carcinoma. Proc Am Soc Clin Oncol 2000;19:266a.